Belluscura Regulatory News (BELL)

Belluscura plc

("Belluscura" or the "Company")

Belluscura Launches Direct to Consumer Sales and Rental Program

.

LONDON, U.K., PLANO, TX, U.S. and SHENZHEN, CHINA (24 October 2023). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that early results on the two-month-old direct to consumer program have exceeded the Board's initial expectations.

The Company has introduced a three-prong direct sales, leasing and short-term rental program for its established X-PLOR® device that has been well received by customers. Recognising a significant need and opportunity to provide portable oxygen concentrators to customers not previously served by durable medical equipment companies, the Company designed a program intended to capture a meaningful underserved population of people suffering from lung disease.

The Company sees this program expanding significantly with the launch of the DISCOV-R? portable oxygen concentrator.

Bob Fary, Senior Vice President Sales and Marketing Belluscura plc, commented:

"I am very excited about the new direct-to consumer sales program. We have identified a potentially significant sales opportunity that not only benefits the Company, but underrepresented patients as well."

For further information please contact:

About Belluscura plc (www.Belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.